Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ET Receptor Antagonist 2 (Compound 16j) is an orally active ET receptor antagonist with an IC50 of 0.22 nM, suitable for pulmonary arterial hypertension (PAH) research. It has been shown to mitigate monocrotaline-induced PAH in a rat model [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | ET Receptor Antagonist 2 (Compound 16j) is an orally active ET receptor antagonist with an IC50 of 0.22 nM, suitable for pulmonary arterial hypertension (PAH) research. It has been shown to mitigate monocrotaline-induced PAH in a rat model [1]. |
In vivo | ET receptor antagonist 2 (compound 16j), administered orally at doses of 150 mg/kg/day and 300 mg/kg/day beginning 48 hours after MCT treatment for a total of 21-26 days, significantly reduced mean pulmonary arterial pressure (mPAP) levels and decreased the levels of HIF1α, ANP, and TNNI3 in rats exposed to MCT. This compound demonstrated antioxidant properties and inhibited lipid peroxidation [1]. |
Molecular Weight | 471.53 |
Formula | C22H25N5O5S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ET receptor antagonist 2 Endocrinology/Hormones Estrogen Receptor/ERR inhibitor inhibit